PETV
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.07 | $286,108 | -$1M |
| 2025 Q2 | -0.11 | $303,284 | -$2M |
| 2025 Q1 | -0.10 | $297,500 | -$2M |
| 2025 Q4 | -0.12 | $224,750 | -$2M |
| 2024 Q3 | -0.09 | $583,313 | -$984,848 |
| 2024 Q2 | -0.11 | $200,720 | -$2M |
| 2024 Q1 | -0.11 | $123,751 | -$2M |
| 2024 Q4 | -0.19 | $48,266 | -$2M |